论文部分内容阅读
目的探讨女性生殖系统弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)临床病理特征。方法收集作者医院女性生殖系统弥漫性B细胞淋巴瘤13例,总结其临床资料和病理学特点。结果根据免疫表型分类,10例为生发中心B细胞样DLBCL,3例为非生发中心B细胞样DLBCL;免疫组织化学:13例CD20、PAX-5及CD79α均(+),CD3、CD43、CD45RO均(-),7例EMA(+),9例CD10(+),11例Bcl-6(+)、9例MUM-1(+);Ki-67阳性指数:1例≤59%,3例为60%~89%,9例>90%;手术治疗13例,10例术后给予环磷酰胺+阿霉素+长春新碱+强的松(CHOP)方案化疗;全部病例获得随访,生存期3~20个月。结论女性生殖系统DLBCL少见,临床易漏诊且侵袭性较高,因此准确完整的掌握其病理学特征对后期治疗十分重要。
Objective To investigate the clinicopathological features of female reproductive system diffuse large B cell lymphoma (DLBCL). Methods A total of 13 cases of diffuse B-cell lymphoma of female reproductive system were collected from the hospital, and their clinical data and pathological features were summarized. Results According to the immunophenotypic classification, 10 cases were germinal center B cell-like DLBCL and 3 cases were non-germinal center B cell-like DLBCL. Immunohistochemistry: 13 cases of CD20, PAX-5 and CD79α, CD3, CD43, 7 cases of EMA (+), 9 cases of CD10 (+), 11 cases of Bcl-6 (+) and 9 cases of MUM-1 3 cases were 60% ~ 89%, 9 cases> 90%; 13 cases were treated by surgery, and 10 cases were treated with cyclophosphamide + doxorubicin + vincristine + prednisone (CHOP) , Survival of 3 to 20 months. Conclusion Female reproductive system DLBCL rare, clinically misdiagnosed and highly invasive, so accurate and complete grasp of the pathological features of the latter part of the treatment is very important.